Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study


Por: Chaparro, M, Baston-Rey, I, Fernandez-Salgado, E, Garcia, JG, Ramos, L, Palomares, MTDL, Arguelles-Arias, F, Flores, EI, Cabello, M, Iturria, SR, Ortiz, AN, Charro, M, Ginard, D, Sadornil, CD, Ochoa, OM, Busquets, D, Iyo, E, Casbas, AG, de la Piscina, PR, Bosca-Watts, MM, Arroyo, M, Garcia, MJ, Hinojosa, E, Gordillo, J, Montiel, PM, Jimenez, BV, Ivorra, CQ, Moron, JMV, Huguet, JM, Gonzalez-Lama, Y, Santos, AIM, Amo, VM, Martin-Arranz, MD, Bermejo, F, Cadilla, JM, de Celix, CR, Salazar, PF, San Roman, AL, Jimenez, N, Lopez, SG, Figuerola, A, Jimenez, I, Cerezo, FJM, Taxonera, C, Varela, P, de Francisco, R, Monfort, D, Arriero, GM, Camba, AH, Garcia-Alonso, FJ, Van Domselaar, M, Villarroya, RP, Nunez, A, Moranta, FR, Marin-Jimenez, I, Alonso, VR, Rodriguez, MDM, Camo-Monterde, P, Tercero, IG, Llavat, MN, Garcia, LA, Cruz, DH, Sulleiro, S, Novella, C, Vispo, E, Barreiro-de Acosta, M, Gisbert, JP

Publicada: 2 nov 2022 Ahead of Print: 1 feb 2022
Resumen:
Background Large real-world-evidence studies are required to confirm the durability of response, effectiveness, and safety of ustekinumab in Crohn's disease (CD) patients in real-world clinical practice. Methods A retrospective, multicentre study was conducted in Spain in patients with active CD who had received >= 1 intravenous dose of ustekinumab for >= 6 months. Primary outcome was ustekinumab retention rate; secondary outcomes were to identify predictive factors for drug retention, short-term remission (week 16), loss of response and predictive factors for short-term efficacy and loss of response, and ustekinumab safety. Results A total of 463 patients were included. Mean baseline Harvey-Bradshaw Index was 8.4. A total of 447 (96.5%) patients had received prior biologic therapy, 141 (30.5%) of whom had received >= 3 agents. In addition, 35.2% received concomitant immunosuppressants, and 47.1% had >= 1 abdominal surgery. At week 16, 56% had remission, 70% had response, and 26.1% required dose escalation or intensification; of these, 24.8% did not subsequently reduce dose. After a median follow-up of 15 months, 356 (77%) patients continued treatment. The incidence rate of ustekinumab discontinuation was 18% per patient-year of follow-up. Previous intestinal surgery and concomitant steroid treatment were associated with higher risk of ustekinumab discontinuation, while a maintenance schedule every 12 weeks had a lower risk; neither concomitant immunosuppressants nor the number of previous biologics were associated with ustekinumab discontinuation risk. Fifty adverse events were reported in 39 (8.4%) patients; 4 of them were severe (2 infections, 1 malignancy, and 1 fever). Conclusions Ustekinumab is effective and safe as short- and long-term treatment in a refractory cohort of CD patients in real-world clinical practice. Lay Summary This large retrospective study demonstrated the short- and long-term effectiveness and safety of ustekinumab in patients with Crohn's disease in real-world clinical practice, including those with refractory disease.

Filiaciones:
Chaparro, M:
 Univ Autonoma Madrid, Hosp Univ La Princesa, Gastroenterol Dept, Inst Invest Sanitaria Princesa, Madrid, Spain

 Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain

Baston-Rey, I:
 Complejo Hosp Univ Santiago, Gastroenterol Dept, Santiago De Compostela, Spain

Fernandez-Salgado, E:
 Complejo Hosp Pontevedra, Gastroenterol Dept, Pontevedra, Spain

Garcia, JG:
 Hosp Publ Comarcal Inmaculada, Gastroenterol Dept, Almeria, Spain

Ramos, L:
 Hosp Univ Canarias, Gastroenterol Dept, Tenerife, Spain

Palomares, MTDL:
 Hosp Univ A Coruna, Gastroenterol Dept, La Coruna, Spain

Arguelles-Arias, F:
 Univ Seville, Hosp Univ Virgen Macarena, Fac Med, Gastroenterol Dept, Seville, Spain

Flores, EI:
 Univ Cordoba, Hosp Univ Reina Sofia, Inst Maimonides Invest Biomed Cordoba, Gastroenterol Dept, Cordoba, Spain

Cabello, M:
 Hosp Univ Virgen de Valme, Gastroenterol Dept, Seville, Spain

Iturria, SR:
 Complejo Hosp Navarra, Gastroenterol Dept, Pamplona, Spain

Ortiz, AN:
 Hosp Univ Virgen del Rocio, Gastroenterol Dept, Seville, Spain

Charro, M:
 Hosp Barbastro, Gastroenterol Dept, Barbastro, Spain

Ginard, D:
 Hosp Univ Son Espases, Gastroenterol Dept, Palma De Mallorca, Spain

Sadornil, CD:
 Hosp San Pedro de Alcantara, Gastroenterol Dept, Caceres, Spain

Ochoa, OM:
 Hosp Univ Cruces, Gastroenterol Dept, Baracaldo, Spain

Busquets, D:
 Hosp Univ Girona Doctor Josep Trueta, Gastroenterol Dept, Girona, Spain

Iyo, E:
 Hosp Comarcal Inca, Gastroenterol Dept, Inca, Spain

Casbas, AG:
 Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain

 Hosp Gen Univ Alicante, Inst Invest Sanitaria & Biomed Alicante, Gastroenterol Dept, Alicante, Spain

de la Piscina, PR:
 Hosp Univ Araba Txagorritxu, Gastroenterol Dept, Araba Txagorritxu, Spain

Bosca-Watts, MM:
 Hosp Clin Univ Valencia, Gastroenterol Dept, Valencia, Spain

Arroyo, M:
 Hosp Clin Univ Lozano Blesa, Gastroenterol Dept, Zaragoza, Spain

Garcia, MJ:
 Hosp Univ Marques de Valdecilla, Inst Invest Sanitario Valdecilla IDIVAL, Gastroenterol Dept, Santander, Spain

Hinojosa, E:
 Hosp Manises, Gastroenterol Dept, Manises, Spain

Gordillo, J:
 Hosp Santa Creu & Sant Pau, Gastroenterol Dept, Barcelona, Spain

Montiel, PM:
 Hosp Univ 12 Octubre, Gastroenterol Dept, Madrid, Spain

Jimenez, BV:
 Hosp Clin Univ Valladolid, Gastroenterol Dept, Valladolid, Spain

Ivorra, CQ:
 Hosp Marina Baixa, Gastroenterol Dept, Villajoyosa, Spain

Moron, JMV:
 Hosp Univ Juan Ramon Jimenez, Gastroenterol Dept, Huelva, Spain

Huguet, JM:
 Hosp Gen Univ Valencia, Gastroenterol Dept, Valencia, Spain

Gonzalez-Lama, Y:
 Hosp Univ Puerta de Hierro, Gastroenterol Dept, Majadahonda, Spain

Santos, AIM:
 Hosp Univ Donostia, Gastroenterol Dept, Donostia San Sebastian, Spain

Amo, VM:
 Hosp Reg Malaga, Gastroenterol Dept, Malaga, Spain

Martin-Arranz, MD:
 Univ Autonoma Madrid, Hosp Univ La Paz, Inst Hlth Res La Paz, Gastroenterol Dept, Madrid, Spain

Bermejo, F:
 Hosp Univ Fuenlabrada, Inst Invest Sanitaria Hosp La Paz, Gastroenterol Dept, Madrid, Spain

Cadilla, JM:
 Hosp Alvaro Cunqueiro, Gastroenterol Dept, Vigo, Spain

de Celix, CR:
 Univ Autonoma Madrid, Hosp Univ La Princesa, Gastroenterol Dept, Inst Invest Sanitaria Princesa, Madrid, Spain

 Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain

Salazar, PF:
 Hosp Virgen de la Concha, Gastroenterol Dept, Zamora, Spain

San Roman, AL:
 Hosp Univ Ramon y Cajal, Gastroenterol Dept, Madrid, Spain

Jimenez, N:
 Hosp Gen Univ Elche, Gastroenterol Dept, Elche, Spain

Lopez, SG:
 Hosp Univ Miguel Servet, Gastroenterol Dept, Zaragoza, Spain

Figuerola, A:
 Hosp Gen Univ Castellon, Gastroenterol Dept, Castellon De La Plana, Spain

Jimenez, I:
 Hosp Univ Galdakao Usansolo, Gastroenterol Dept, Galdakao, Spain

 Hosp Gen Univ Gregorio Maranon, Serv Aparato Digest, IiSGM, Madrid, Spain

 Univ Complutense Madrid, Fac Med, Madrid, Spain

Cerezo, FJM:
 Hosp Univ St Joan Reus, Gastroenterol Dept, Reus, Spain

Taxonera, C:
 Hosp Clin Univ San Carlos, Hosp Clin San Carlos, Gastroenterol Dept, Inst Invest, Madrid, Spain

Varela, P:
 Hosp Univ Cabuenes, Gastroenterol Dept, Gijon, Spain

de Francisco, R:
 Hosp Univ Cent Asturias, Inst Invest Biosanitaria Principado Asturias, Gastroenterol Dept, Oviedo, Spain

Monfort, D:
 Consorci Sanitari Terrassa, Gastroenterol Dept, Terrassa, Spain

Arriero, GM:
 Complejo Hosp Univ Ferrol, Gastroenterol Dept, Ferrol, Spain

Camba, AH:
 Hosp Univ Nuestra Senora Candelaria, Gastroenterol Dept, Santa Cruz De Tenerife, Spain

Garcia-Alonso, FJ:
 Hosp Univ Rio Hortega, Gastroenterol Dept, Valladolid, Spain

Van Domselaar, M:
 Hosp Univ Torrejon, Gastroenterol Dept, Madrid, Spain

Villarroya, RP:
 Hosp Univ Infanta Sofia, Gastroenterol Dept, Madrid, Spain

Nunez, A:
 Hosp Clin Univ Salamanca, Gastroenterol Dept, Salamanca, Spain

Moranta, FR:
 Hosp Univ Bellvitge, Gastroenterol Dept, Barcelona, Spain

Marin-Jimenez, I:
 Hosp Gen Univ Gregorio Maranon, Serv Aparato Digest, IiSGM, Madrid, Spain

 Univ Complutense Madrid, Fac Med, Madrid, Spain

Alonso, VR:
 Hosp Univ Vall dHebron, Gastroenterol Dept, Barcelona, Spain

Rodriguez, MDM:
 Hosp Univ Virgen de las Nieves, Gastroenterol Dept, Granada, Spain

Camo-Monterde, P:
 Hosp Univ San Jorge, Gastroenterol Dept, Huesca, Spain

Tercero, IG:
 Hosp Gen Univ Santa Lucia, Gastroenterol Dept, Cartagena, Spain

Llavat, MN:
 Gastroenterol Dept, Hosp St Joan Despi Moises Broggi, St Joan Despi, Spain

Garcia, LA:
 Hosp Univ Burgos, Gastroenterol Dept, Burgos, Spain

Cruz, DH:
 Hosp Gen Univ Ciudad Real, Gastroenterol Dept, Ciudad Real, Spain

Sulleiro, S:
 Janssen Med Dept, Madrid, Spain

Novella, C:
 Janssen Med Dept, Madrid, Spain

Vispo, E:
 Janssen Med Dept, Madrid, Spain

Barreiro-de Acosta, M:
 Complejo Hosp Univ Santiago, Gastroenterol Dept, Santiago De Compostela, Spain

Gisbert, JP:
 Univ Autonoma Madrid, Hosp Univ La Princesa, Gastroenterol Dept, Inst Invest Sanitaria Princesa, Madrid, Spain

 Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain
ISSN: 10780998





INFLAMMATORY BOWEL DISEASES
Editorial
OXFORD UNIV PRESS INC, JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 28 Número: 11
Páginas: 1725-1736
WOS Id: 000764517700001
ID de PubMed: 35166347
imagen hybrid, All Open Access, Hybrid Gold

MÉTRICAS